NCT07128550Phase 3Active not recruiting

A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide

Study sponsor: Vir Biotechnology, Inc. · VIR

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-12Estimated

Enrollment · participants150Estimated

Source updated2026-07-13Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-07-13 · 1 field changed

Recruitment status changed

− Before

~~Recruiting~~

+ After

Active not recruiting

Check registry source

Study details

Conditions studied

Viral Hepatitis

Treatments or interventions studied

TobevibartDrugAlso known as VIR-3434
ElebsiranDrugAlso known as VIR-2218
BulevirtideDrugAlso known as Hepcludex

Primary outcomes · main study measures

measure: HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 24; timeFrame: Week 24; measure: HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) 24 weeks after end of treatment.; timeFrame: 24 Weeks after End of Treatment

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history